

UNCLASSIFIED

AD NUMBER
ADB232089
NEW LIMITATION CHANGE
TO Approved for public release, distribution unlimited
FROM Distribution authorized to U.S. Gov't. agencies only; Proprietary Information; Aug 97. Other requests shall be referred to US Army Medical Research and Materiel Command, 504 Scott St., Fort Detrick, MD 21702-5012.
AUTHORITY
USAMRMC ltr, dtd 21 Feb 2003

THIS PAGE IS UNCLASSIFIED

AD _____

AWARD NUMBER DAMD17-96-1-6123

TITLE: Design, Synthesis, and Testing of Breast Cancer
Angiogenesis Inhibitors

PRINCIPAL INVESTIGATOR: Edward L. Schwartz, Ph.D.

CONTRACTING ORGANIZATION: Montefiore Medical Center
Bronx, New York 10467

REPORT DATE: August 1997

TYPE OF REPORT: Annual

PREPARED FOR: Commander
U.S. Army Medical Research and Materiel Command
Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Distribution authorized to U.S. Government
agencies only (proprietary information, August 1997). Other
requests for this document shall be referred to U.S. Army Medical
Research and Materiel Command, 504 Scott Street, Fort Detrick,
Maryland 21702-5012.

The views, opinions and/or findings contained in this report are
those of the author(s) and should not be construed as an official
Department of the Army position, policy or decision unless so
designated by other documentation.

19971218 008

DTIC QUALITY INSPECTED 4

REPORT DOCUMENTATION PAGE

Form Approved
OMB No. 0704-0188

Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing the collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden, to Washington Headquarters Services, Directorate for Information Operations and Reports, 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302, and to the Office of Management and Budget, Paperwork Reduction Project (0704-0188), Washington, DC 20503.

1. AGENCY USE ONLY (Leave blank)		2. REPORT DATE August 1997	3. REPORT TYPE AND DATES COVERED Annual (15 Jul 96 - 14 Jul 97)	
4. TITLE AND SUBTITLE Design, Synthesis, and Testing of Breast Cancer Angiogenesis Inhibitors			5. FUNDING NUMBERS DAMD17-96-1-6123	
6. AUTHOR(S) Edward L. Schwartz, Ph.D				
7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) Montefiore Medical Center Bronx, NY 10467			8. PERFORMING ORGANIZATION REPORT NUMBER	
9. SPONSORING/MONITORING AGENCY NAME(S) AND ADDRESS(ES) Commander U.S. Army Medical Research and Materiel Command Fort Detrick, Frederick, Maryland 21702-5012			10. SPONSORING/MONITORING AGENCY REPORT NUMBER	
11. SUPPLEMENTARY NOTES				
12a. DISTRIBUTION / AVAILABILITY STATEMENT Distribution authorized to U.S. Government agencies only (proprietary information, August 1997). Other requests for this document shall be referred to U.S. Army Medical Research and Materiel Command, 504 Scott Street, Fort Detrick, Maryland 21702-5012.			12b. DISTRIBUTION CODE	
13. ABSTRACT (Maximum 200) Tumor angiogenesis is the process by which a growing tumor mass recruits the new blood vessels required for its continued growth, and through which the tumor can spread to distant sites. Indeed the neovascularization process is thought to be one of the rate limiting steps for the growth of primary and metastatic breast tumors. This proposal will focus on the development of inhibitors of a particular angiogenic factor, thymidine phosphorylase/platelet-derived endothelial cell growth factor (TP/PD-ECGF). These inhibitors will target the enzymatic activity of TP/PD-ECGF, since it has been found to be required for angiogenesis. In the past year, several compounds have been synthesized, with one showing good enzyme inhibitory activity <i>in vitro</i> (IC ₅₀ = 30 μM). These compounds will form the basis for further exploration of structure-activity relationships.				
14. SUBJECT TERMS Breast Cancer ; Drug design; tumor angiogenesis inhibitors; platelet-derived endothelial cell growth factor; thymidine phosphorylase; human breast cancer xenografts; structure-activity relationships.			15. NUMBER OF PAGES 13	
			16. PRICE CODE	
17. SECURITY CLASSIFICATION OF REPORT Unclassified	18. SECURITY CLASSIFICATION OF THIS PAGE Unclassified	19. SECURITY CLASSIFICATION OF ABSTRACT Unclassified	20. LIMITATION OF ABSTRACT Limited	

FOREWORD

Opinions, interpretations, conclusions and recommendations are those of the author and are not necessarily endorsed by the U.S. Army.

____ Where copyrighted material is quoted, permission has been obtained to use such material.

____ Where material from documents designated for limited distribution is quoted, permission has been obtained to use the material.

____ Citations of commercial organizations and trade names in this report do not constitute an official Department of Army endorsement or approval of the products or services of these organizations.

X In conducting research using animals, the investigator(s) adhered to the "Guide for the Care and Use of Laboratory Animals," prepared by the Committee on Care and Use of Laboratory Animals of the Institute of Laboratory Resources, National Research Council (NIH Publication No. 86-23, Revised 1985).

____ For the protection of human subjects, the investigator(s) adhered to policies of applicable Federal Law 45 CFR 46.

____ In conducting research utilizing recombinant DNA technology, the investigator(s) adhered to current guidelines promulgated by the National Institutes of Health.

____ In the conduct of research utilizing recombinant DNA, the investigator(s) adhered to the NIH Guidelines for Research Involving Recombinant DNA Molecules.

____ In the conduct of research involving hazardous organisms, the investigator(s) adhered to the CDC-NIH Guide for Biosafety in Microbiological and Biomedical Laboratories.

Ed Schatz
PI - Signature

8/11/97
Date

Table of Contents

Cover page	1
Report documentation page	2
Foreword	3
Table of contents	4
Introduction	5
Body of report	6-7
Conclusion	7
References	8-9
Appendix	10-13

Introduction. There is a need for alternative approaches to treat metastatic breast cancer. One rapidly developing area of investigation is the study of tumor angiogenesis, the process by which a growing tumor mass recruits the new blood vessels required for its continued growth, and through which the tumor can spread to distant sites. Indeed the neovascularization process is thought to be one of the rate limiting steps for the growth of primary and metastatic tumors.¹⁻² Most studies have demonstrated the importance of angiogenesis in the progression of human breast malignancies and found the extent of vascularization to be correlated with tumor size and an indicator of node metastasis.³⁻⁶ Quantitative pathology studies in early breast cancer have shown a worse prognosis for those patients with highly vascular tumors, and similar results were obtained in studies of both node-negative and node-positive breast carcinomas.⁵⁻⁸ Further, the prognostic influence of tumor angiogenesis was independent of other prognostic indicators.

Several polypeptides and growth factors that are produced by breast cancer epithelial and stromal cells have been identified as having endothelial cell mitogenicity and angiogenic activity: TGF α and β (transforming growth factor), VEGF (vascular endothelial growth factor), PD-ECGF (platelet-derived endothelial cell growth factor), FGF (fibroblast growth factor) and TNF α (tumor necrosis factor).^{1,9} Our studies are focusing on the angiogenic factor PD-ECGF, based on recent evidence demonstrating its role in experimental and human cancer, and the finding that PD-ECGF is identical to human thymidine phosphorylase (TP), an enzyme that catalyzes the reversible conversion of thymine to thymidine.¹⁰⁻¹² When transfected into NIH 3T3 cells, TP/PD-ECGF was found to increase the vascularization of tumors growing in nude mice after sc inoculation.¹³ Similarly, overexpressing TP/PD-ECGF in MCF7 breast carcinoma cells markedly increased tumor growth *in vivo*, although it had no effect on the growth of the cells *in vitro*.¹⁴ Western blot analysis of primary human breast tissue showed that TP/PD-ECGF expression was elevated in the tumors compared to the normal tissue¹⁴, a finding which provides clinical relevance to the transfection experiments.

Studies suggest that the angiogenic and endothelial cell chemotactic activities of PD-ECGF are dependent upon its enzymatic activity, and this has been confirmed with site-directed mutagenesis studies.^{14,15-17} Of the angiogenic factors identified to date, TP/PD-ECGF is the only one in which an enzymatic activity of the factor is required for angiogenic activity. These observations serve as the basis for our hypothesis that inhibition of the catalytic activity of TP/PD-ECGF will also block its angiogenic properties. By synthesizing inhibitors of TP/PD-ECGF, we will be able to test this hypothesis and provide a basis for the development of a novel class of antitumor agents. There are no potent and specific inhibitors of TP/PD-ECGF currently available.

PROPRIETARY**Methods, Results, Discussion****Progress in the Synthesis and Evaluation of Target Compounds:**

We had originally proposed the synthesis of four general, structurally distinct classes of pyrimidines or pyrimidine nucleosides to be evaluated as potential TP/PD-ECGF inhibitors. These four classes (I-IV) are illustrated in Fig. 1 (see Appendix). We can now report significant progress in the synthesis and evaluation of two of these classes, namely I and III.

The synthesis of the 2'-deoxypseudouridines of class III was tackled first because of the relative complexity of the route anticipated. Our choice of this class of C-nucleoside analogues as potential inhibitors of PD-ECGF was based on the stereo electronic similarities that exist between these and thymidine, a natural substrate for the enzyme. The synthetic route originally envisaged had to be modified substantially and the method finally adopted is illustrated in Fig.2. A key modification involved the protection of the two hydroxyl groups in compounds **2-5** by acetylation without which a complex mixture of products (as well as unreacted material) was obtained. The first member of this class, 1-methyl-2'-deoxyuridine (**2-7**), unexpectedly was found to have little inhibitory activity ($IC_{50} > 4$ mM, see table 1). The enzyme, however, can accommodate 2'-deoxyuridines with 5-substituents as large as 2-bromovinyl and propynoxy groups. It is expected, therefore, that the successful synthetic methodology we have just developed to obtain **2-7** will make it also possible to access 2'-deoxypseudouridines bearing N-1 substituents other than methyl and with greater capacity to inhibit TP/PD-ECGF.

As we had proposed originally, we have synthesized several variously substituted derivatives of 6-aminouracils (Class I inhibitors) to maximize binding to the enzyme and thereby identify compounds with greater potency and specificity. One of our synthetic routes is illustrated in Fig.3 and makes use of the direct nucleophilic displacement of Cl from 6-chlorouracil by a variety of amines. Of the compounds obtained, **3-1a** - **3-1f**, the most active appear to be those where the substitution at C-6 incorporates two phenyl rings connected by a two atom bridge (**3-1e** and **3-1f** with IC_{50s} of 114 μ M and 30 μ M, respectively). Current synthetic efforts are focusing on the investigation of several new compounds with this same substitution pattern in order to fine tune and further maximize binding to the enzyme. Compounds **3-1g** and **3-1h** (which are now being synthesized in our laboratory) are two examples of this new series of potential inhibitors.

We have also begun the synthesis (see Fig. 4) of a new series of analogs to find out whether structural extension of the aminosubstituents on C-6 of uracil by a short distance might not enhance the inhibitory activity of Class III inhibitors. The new derivatives obtained to date (**4-1c**, **4-1d**, and **4-1e**) differ from their homologues of Fig.3 only by a single methylene group inserted between C-6 and the amino substituent. We had shown that 5-bromo-6-aminouracil is an effective inhibitor of human TP/PD-ECGF, with an K_i of 13 μ M and is, therefore, one of the best inhibitor

PROPRIETARY

of this enzyme known to date. It would be of interest to find out therefore whether 6-aminouracil derivatives with 5-substituents other than Br might not also exhibit similar or possibly even better activities. Preliminary synthetic studies in our laboratory would seem to indicate that (as shown in Fig. 5) 6-aminouracil reacts with aromatic isothiocyanates to give the C-5 substituted thioamide product (and not, as might be expected, the C-6 thioureido derivative). If confirmed, this synthetic method might open access to many new analogs of 5-bromo-6-aminouracil with groups other than the halogens and with various steric requirements. These preliminary findings and the activity of the product obtained so far (**5-1a**, **5-1b** and **5-1c**) are now under active investigation.

Conclusions. The synthesis of several 2'-deoxypseudouridines C-nucleosides and derivatives of 6-aminouracil has been completed. The latter have shown good activity, with the 5-bromo-substituted compound and a C6 derivative which incorporates two phenyl rings connected by a two atom bridge being the most potent.

REFERENCES

1. Folkman J and Shing Y (1992) Angiogenesis. *J. Biol. Chem.* 267:10931-10934.
2. Hayes DF (1994) Angiogenesis and breast cancer. *Hematology-Oncology Clinics of North America* 8:51-71.
3. Weidner N, Semple, JP, Welch WR and Folkman J (1991) Tumor angiogenesis and metastasis: correlation in invasive breast carcinoma. *N. Engl. J. Med.* 324:1-8.
4. Horak ER, Leek R, Klenk N, LeJeune S, Smith K, Stuart N, Greenall M, Stepniowska K and Harris AL (1993) Angiogenesis, assessed by platelet/endothelial cell adhesion molecule antibodies, as indicator of node metastases and survival in breast cancer. *Lancet* 340:1120-1124.
5. Toi M, Kashitani J and Tominaga T (1993) Tumor angiogenesis is an independent prognostic indicator in primary breast carcinoma. *Int. J. Cancer* 55:371-374.
6. Gasparini G, Weidner N, Bevilacqua P. et. al. (1994) Tumor microvessel density, p53 expression, tumor size, and peritumoral lymphatic vessel invasion are relevant prognostic markers in node-negative breast carcinoma. *J. Clin. Oncol.* 12:454-466.
7. Fox SB, Leek RD, Smith K, Hollyer J, Greenall M, Harris AL (1994) tumor angiogenesis in node-negative breast carcinomas- relationship with epidermal growth factor receptor, estrogen receptor, and survival. *Breast Cancer Res. Treat.* 29:109-116.
8. Craft PS and Harris AL (1994) Clinical prognostic significance of tumor angiogenesis. *Annals of Oncology* 5:305-311.
9. Hlatky L, Tsionou C, Hahnfeldt P and Coleman CN (1994) Mammary fibroblasts may influence breast tumor angiogenesis via hypoxia-induced vascular endothelial growth factor up-regulation and protein expression. *Cancer Res.* 54:6083-6086.
10. Moghaddam A and Bicknell R (1992) Expression of PD-ECGF factor in *E. coli* and confirmation of its thymidine phosphorylase activity. *Biochemistry* 31:12141-12146.
11. Furukawa T, Yoshimura A, Sumizawa T, Haraguchi M, Akiyama S-I, Fukui K, Ishizawa M and Yamada Y (1992) Angiogenic factor. *Nature* 356:668.
12. Sumizawa T, Furukawa T, Haraguchi M, Yoshimura A, Takeyasu A, Ishizawa M, Yamada Y and Akiyama S-I (1993) Thymidine phosphorylase activity associated with platelet-derived endothelial cell growth factor. *J. Biochem.* 114: 9-14.
13. Ishikawa F, Miyazono K, Hellman U, Drexler H, Wernstedt C, Hagiwara K, Usuki K, Takaku F, Risau W and Heldin C-H (1989) Identification of angiogenic activity and the cloning and expression of platelet-derived endothelial cell growth factor. *Nature* 338: 557-562.

14. Moghaddam A, Zhang H-T, Fan T-P D, Hu D-E, Lees VC, Turley H, Fox SB, Gatter KC, Harris AL and Bicknell R (1995) Thymidine phosphorylase is angiogenic and promotes tumor growth. *Proc. Nat. Acad. Sci.* 92:998-1002.
15. Haraguchi M, Miyadera K, Uemura K, Sumizawa T, Furukawa T, Yamada K, Akiyama S-I, and Yamada Y (1992) Angiogenic activity of enzymes. *Nature* 368:198-199.
16. Finnis C, Dodsworth N, Pollitt CE, Carr G and Sleep D (1993) Thymidine phosphorylase activity of platelet-derived endothelial cell growth factor is responsible for endothelial cell mitogenicity. *Eur. J. Biochem.* 212:201-210.
17. Miyadera K, Sumizawa T, Haraguchi M, Yoshida H, Konstanty W, Yamada Y and Akiyama S (1995) Role of thymidine phosphorylase activity in the angiogenic effect of platelet-derived endothelial cell growth factor/thymidine phosphorylase. *Cancer Res.* 55:1687-1690.

PROPRIETARY

APPENDIX

Fig. 1




Figure 1: Classes of compounds to be synthesized and tested as inhibitors of TP/PD-ECGF catalytic activity.


PROPRIETARY

Figure 2: Synthetic route utilized for the synthesis of class III compounds.


PROPRIETARY

Figure 3: Synthetic route utilized for the synthesis of 6-aminouracil derivatives by direct nucleophilic displacement.

Figure 4: 6-Aminouracil derivatives with a methylene group inserted between C-6 and the amino substituent.

Figure 5: 6-Aminouracil reacts with aromatic isothiocyanates to give the C-5 substituted thioamide product, and not the C-6 thioureido derivative.

PROPRIETARY**Table 1: Inhibition of TP/PD-ECGF activity.**TP Inhibitory activity of synthesized target compounds (7 / 20 / 97)

Class of TP Inhibitors	Compound (Substituent)	IC50 (Human Recomb. TP)	IC50 (Rabbit Liver TP)
Class III	1-5 (R=Me), 2-7	>4 mM (Inactive)	----
Class I	3-1 (R = a)	220 μ M	170 μ M
	3-1 (R = b)	275 μ M	170 μ M
	3-1 (R = c)	160 μ M	74 μ M
	3-1 (R = d)	122 μ M	53 μ M
	3-1 (R = e)	114 μ M	----
	3-1 (R = f)	30 μ M	14 μ M



DEPARTMENT OF THE ARMY
US ARMY MEDICAL RESEARCH AND MATERIEL COMMAND
504 SCOTT STREET
FORT DETRICK, MARYLAND 21702-5012

REPLY TO
ATTENTION OF:

MCMR-RMI-S (70-1y)

21 Feb 03

MEMORANDUM FOR Administrator, Defense Technical Information
Center (DTIC-OCA), 8725 John J. Kingman Road, Fort Belvoir,
VA 22060-6218

SUBJECT: Request Change in Distribution Statement

1. The U.S. Army Medical Research and Materiel Command has reexamined the need for the limitation assigned to technical reports written for this Command. Request the limited distribution statement for the enclosed accession numbers be changed to "Approved for public release; distribution unlimited." These reports should be released to the National Technical Information Service.

2. Point of contact for this request is Ms. Kristin Morrow at DSN 343-7327 or by e-mail at Kristin.Morrow@det.amedd.army.mil.

FOR THE COMMANDER:

A handwritten signature in black ink, appearing to read "Phyllis M. Rinehart".

PHYLLIS M. RINEHART
Deputy Chief of Staff for
Information Management

Encl

ADB263458	ADB282838
ADB282174	ADB233092
ADB270704	ADB263929
ADB282196	ADB282182
ADB264903	ADB257136
ADB268484	ADB282227
ADB282253	ADB282177
ADB282115	ADB263548
ADB263413	ADB246535
ADB269109	ADB282826
ADB282106	ADB282127
ADB262514	ADB271165
ADB282264	ADB282112
ADB256789	ADB255775
ADB251569	ADB265599
ADB258878	ADB282098
ADB282275	ADB232738
ADB270822	ADB243196
ADB282207	ADB257445
ADB257105	ADB267547
ADB281673	ADB277556
ADB254429	ADB239320
ADB282110	ADB253648
ADB262549	ADB282171
ADB268358	ADB233883
ADB257359	ADB257696
ADB265810	ADB232089
ADB282111	ADB240398
ADB273020	ADB261087
ADB282185	ADB249593
ADB266340	ADB264542
ADB262490	ADB282216
ADB266385	ADB261617
ADB282181	ADB269116
ADB262451	
ADB266306	
ADB260298	
ADB269253	
ADB282119	
ADB261755	
ADB257398	
ADB267683	
ADB282231	
ADB234475	
ADB247704	
ADB258112	
ADB267627	